NeurAxis

NeurAxis occupies a focused position within medical devices and digital-adjacent therapeutics, concentrating on neuromodulation for disorders of gut-brain interaction rather than competing across the entire neurotechnology market. Its core differentiator is PENFS, delivered through IB-Stim, a non-surgical device targeting functional abdominal pain associated with IBS, functional dyspepsia, and related nausea symptoms in patients aged eight and older. RED broadens the company’s addressable market into chronic constipation and pelvic floor assessment. NeurAxis is differentiated by combining a pediatric and adult indication focus with clinical research, provider certification, reimbursement development, and patient advocacy. FDA clearance, insurance coverage exceeding 100 million lives, the 2026 Category I CPT code, and the VA contracting pathway provide adoption infrastructure beyond the device itself. However, its relatively small workforce of approximately 11 to 50 employees, limited disclosed investor base, and continuing profitability concerns indicate a narrower scale and higher execution sensitivity than larger diversified medtech competitors.

NeurAxis’s trajectory shows a transition from regulatory and clinical development toward commercialization and reimbursement expansion. Founded in 2011 and publicly listed in 2023, the company raised $3.0 million in post-IPO equity on Nov 14, 2023, followed by $5.0 million on May 21, 2025 and $2.8 million on Oct 1, 2025, for total disclosed funding of $10.8 million. The 2024 FDA 510(k) clearance for IB-Stim expanded the potential patient population, while the May 2025 launch of RED added a second commercial product and a new constipation-focused use case. Revenue growth accelerated in 2025, including 39% growth reported for the first quarter and 22% growth for the third quarter. In 2026, the AMA Category I CPT code and VA Federal Supply Schedule contract created two practical channels for adoption. First-quarter 2026 revenue reportedly increased 79.5% year over year to approximately $1.6 million, with a narrower net loss. The trajectory remains financially constrained: NeurAxis has disclosed going-concern risks, and its small employee base suggests limited operating capacity. New hires in 2024 absorbed services previously handled by consultants, indicating gradual internalization rather than rapid headcount scaling.